MDS is a group of bone marrow disorders that affect the body’s ability to produce a sufficient amount of healthy red blood cells. At least 20 percent of those with MDS will develop acute myeloid leukemia (AML). While the only known cure for MDS is a bone marrow transplant from a healthy donor, fewer than 10 percent of those afflicted by the disease are able to undergo a transplant due to advanced age or a medical problem.
The gift from the Newton-based foundation will establish the Edward P. Evans Center for Myelodysplastic Syndromes at Dana-Farber, which has longstanding research and clinical expertise spanning the spectrum of MDS onset and progression, including genetic predisposition to MDS, early pre-malignant clonal states, lower- and higher-risk MDS, post-MDS AML, and stem cell transplantation. In addition to the gift, Dana-Farber has committed matching funds over the next five years in support of the center.
"Since 2011, the Edward P. Evans Foundation has contributed more than $66 million to medical research directed at improving outcomes and finding a cure for MDS patients," said Evans Foundation president Michael D. Lewis. "Dana-Farber Cancer Institute is the ideal location for our newest Edward P. Evans Center for Myelodysplastic Syndromes, part of the foundation's next phase in progressing the field forward. The new center capitalizes on Dana-Farber's world-renowned faculty, access to patients, and relationship with preeminent Boston-area research organizations. We eagerly anticipate the flow of new discoveries that will benefit MDS patients."